Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510159
Status:
COMPLETED
Last Update Posted:
2008-01-18
First Post:
2007-07-31
Brief Title:
Comparing Praziquantel Versus Artesunate SulfamethoxypyrazinePyrimethamine for Treating Schistosomiasis
Sponsor:
Dafra Pharma
Organization:
Dafra Pharma
Study Overview
Official Title:
Randomized Double Blind Clinical Trial in Mali Comparing the Effectiveness of Artesunate SulfamethoxypyrazinePyrimethamine Versus Praziquantel in the Treatment of S Haematobium in Children
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of praziquantel versus AsSMP Co-Arinate FDC in the treatment of Schistosoma haematobium in 6-15 year old Malian children The nul-hypothesis in this study is that the combination of AsSMP is more effective than praziquantel in the treatment of S haematobium infected children
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None